Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.57 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111987 | 0.81 | NPC1 (0.56) | TAS1R3TAS1R1TAS1R2SPRHPGD | |
| SCHEMBL4119254 | 0.78 | ALDH1A1 (0.52) | TAS1R3TAS1R1TAS1R2HPGDSMN1; SMN2 | |
| SCHEMBL4124894 | 0.77 | TAS1R3 (0.60) | TAS1R3TAS1R1TAS1R2HPGDSMN1; SMN2 | |
| SCHEMBL4118067 | 0.77 | NPC1 (0.53) | TAS1R3TAS1R1TAS1R2HPGDSMN1; SMN2 | |
| SCHEMBL4118921 | 0.76 | SPR (0.54) | SPRHPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4116705 | 0.76 | NOTUM (0.55) | HPGDSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL4106224 | 0.75 | NPC1 (0.48) | TAS1R3TAS1R1TAS1R2SPRNPC1 | |
| SCHEMBL4122873 | 0.74 | NPC1 (0.50) | TAS1R3TAS1R1TAS1R2SPRNPC1 | |
| SCHEMBL4115831 | 0.74 | RAB9A (0.56) | TAS1R3TAS1R1TAS1R2HPGDPOLB | |
| SCHEMBL4118264 | 0.74 | ESR2 (0.49) | TAS1R3TAS1R1TAS1R2SPRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| EP-1968938-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079957-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1968938-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079957-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | PCCA, PPARA, PTGES | TAS1R3 3432/4885TAS1R1 4064/4885TAS1R2 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.